← Eichor
Condition: Wet Amd Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Wet Amd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Phase 4 · 1 location(s) · Medical University of Vienna · NCT05093374MMP-9 Inhibition for Recalcitrant Wet AMD
Phase 2 · 1 location(s) · University of Iowa · NCT04504123A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Phase N/A · 1 location(s) · Guangzhou Jiayin Biotech Ltd · NCT06859515Gene Therapy(FT-003) for Wet AMD
Phase 1/Phase 2 · 1 location(s) · Frontera Therapeutics · NCT06492863A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Phase 2/Phase 3 · 91 location(s) · EyeBiotech Ltd. · NCT07440225Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL
NA · 1 location(s) · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · NCT06893965Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Phase 3 · 31 location(s) · Innostellar Biotherapeutics Co.,Ltd · NCT07317934Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Deg
Phase 3 · 79 location(s) · Adverum Biotechnologies, Inc. · NCT07482176Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Phase 1 · 7 location(s) · Caregen Co. Ltd. · NCT06132035Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Phase N/A · 1 location(s) · Beijing Anlong Biopharmaceutical Co., Ltd. · NCT06718816Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
Phase 1/Phase 2 · 1 location(s) · Fujian Haixi Pharmaceuticals Co., Ltd. · NCT07185841Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · 181 location(s) · AbbVie · NCT05407636Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macul
Phase 3 · 94 location(s) · 4D Molecular Therapeutics · NCT07064759Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to E
Phase 3 · 36 location(s) · King's College Hospital NHS Trust · NCT04663750A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degenera
Phase 1 · 3 location(s) · Youxin Chen · NCT06213038Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
NA · 2 location(s) · Hospices Civils de Lyon · NCT04697095Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degen
Phase 2 · 4 location(s) · Adverum Biotechnologies, Inc. · NCT07630649OCT Angiography in Wet AMD
Phase N/A · 1 location(s) · Oregon Health and Science University · NCT02253030A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Phase 2/Phase 3 · 63 location(s) · EyeBiotech Ltd. · NCT07496567Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
Phase 4 · 1 location(s) · Faculty Hospital Kralovske Vinohrady · NCT06875245Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Phase 1/Phase 2 · 6 location(s) · Eyconis INC. · NCT075875154D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/Phase 2 · 25 location(s) · 4D Molecular Therapeutics · NCT05197270AVIGA3 (Cohort 2.0)
NA · 1 location(s) · Tan Tock Seng Hospital · NCT07255859A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 1 location(s) · Intra-IMMUSG Pte Ltd · NCT07547228Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 9 location(s) · Skyline Therapeutics (US) Inc. · NCT05986864Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
Phase 3 · 4 location(s) · Parc de Salut Mar · NCT06952452A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Phase N/A · 10 location(s) · Skyline Therapeutics · NCT06346600Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Wi
Phase 3 · 1 location(s) · SANGMYUNG innovation · NCT07695207Stem Cell Ophthalmology Treatment Study II
NA · 4 location(s) · MD Stem Cells · NCT03011541
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.